Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Post-transplant EBV induced lymphoproliferative disorders

K G Lucas1, K E Pollok, D J Emanuel

  • 1Department of Pediatrics, Riley Hospital for Children, Indiana University, Indianapolis 46202-5225, USA.

Leukemia & Lymphoma
|March 1, 1997
PubMed
Summary

Epstein Barr virus induced lymphoproliferative disease (EBV-LPD) is a serious post-transplant complication. For bone marrow transplant recipients, donor lymphocyte infusions are effective, while its use in organ transplant patients is under investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Submyeloablative cord blood transplantation corrects clinical defects seen in IPEX syndrome.

Bone marrow transplantation·2006
Same author

Differential transduction efficiency of SCID-repopulating cells derived from umbilical cord blood and granulocyte colony-stimulating factor-mobilized peripheral blood.

Human gene therapy·2001
Same author

Interleukin-5 inhibition of biliary cell chloride currents and bile flow.

American journal of physiology. Gastrointestinal and liver physiology·2001
Same author

Facilitation of retrovirus-mediated gene transfer into hematopoietic stem and progenitor cells and peripheral blood T-lymphocytes utilizing recombinant fibronectin fragments.

Current opinion in molecular therapeutics·2001
Same author

B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen.

Journal of immunology (Baltimore, Md. : 1950)·2000
Same author

A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.

Human gene therapy·2000

Area of Science:

  • Immunology
  • Oncology
  • Transplantation

Background:

  • Epstein Barr virus induced lymphoproliferative disease (EBV-LPD) presents as a spectrum from polyclonal proliferations to malignant lymphoma.
  • EBV-LPD predominantly affects individuals with compromised cellular immunity to Epstein Barr virus (EBV).
  • Diagnosis in transplant recipients necessitates a high index of suspicion due to the critical nature of EBV-LPD.

Purpose of the Study:

  • To differentiate the treatment approaches for EBV-LPD in organ transplant versus bone marrow transplant recipients.
  • To highlight the efficacy of adoptive immunotherapy in bone marrow transplant recipients with EBV-LPD.
  • To investigate the potential of adoptive immunotherapy for EBV-LPD in organ transplant patients.

Main Methods:

  • Comparative analysis of EBV-LPD characteristics and treatment responses in different transplant populations.

Related Experiment Videos

  • Review of treatment outcomes for EBV-LPD, focusing on adoptive immunotherapy.
  • Exploration of ongoing clinical investigations into adoptive immunotherapy for EBV-LPD post-organ transplantation.

    • Main Results:

    • EBV-LPD in organ transplant recipients often involves host-origin lymphomas responsive to reduced immunosuppression.
    • Bone marrow transplant recipients typically develop donor-origin EBV-LPD, less responsive to conservative measures.
    • Adoptive immunotherapy with donor lymphocytes is the established treatment for EBV-LPD in bone marrow transplant recipients, yielding high eradication rates.

    Conclusions:

    • Treatment strategies for EBV-LPD must be tailored to the transplant type (organ vs. bone marrow).
    • Adoptive immunotherapy is a highly effective treatment for EBV-LPD in bone marrow transplant recipients.
    • The application of adoptive immunotherapy for EBV-LPD in organ transplant recipients is an active area of research.